Last reviewed · How we verify
Taurolin (TAUROLIDINE)
Taurolidine works by inhibiting bacterial cell wall synthesis and modulating the immune response.
At a glance
| Generic name | TAUROLIDINE |
|---|---|
| Drug class | Anti-coagulant [EPC] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2023 |
Mechanism of action
Imagine your body's immune system as a defense army. Taurolidine helps the army by blocking the enemy's (bacteria's) ability to build strong walls, making it easier for the army to attack and defeat them. This helps to prevent infections and promote healing.
Approved indications
Common side effects
- Hemodialysis catheter malfunction
- Hemorrhage/bleeding
- Nausea
- Vomiting
- Dizziness
- Musculoskeletal chest pain
- Thrombocytopenia
Serious adverse events
- Serious adverse reactions (overall)
- Adverse reactions leading to death
- Adverse reactions leading to discontinuation
- Heparin-Induced Thrombocytopenia
- Drug Hypersensitivity
- Hypocalcemia
- Dysgeusia
- Paresthesia
Key clinical trials
- Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology (NA)
- Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients (NA)
- Use of a Taurolidine Containing Antimicrobial Wash to Reduce Prosthetic Device Infection After Trauma Surgery
- Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) (PHASE3)
- Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
- Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age (PHASE4)
- Antimicrobial Locks for Hemodialysis Catheter Infections (PHASE2)
- Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |